SCHEMBL200247

SCHEMBL200247

Cc1ccc(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.57
MMP9 P14780 2/20 0.57
PLAU P00749 4/20 0.47
HPN P05981 4/20 0.47
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
CA2 P00918 3/20 0.44
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
MMP13 P45452 2/20 0.42
CA1 P00915 2/20 0.42
MMP1 P03956 1/20 0.42
MMP8 P22894 1/20 0.42
CA14 Q9ULX7 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MMP3 P08254 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL200245 1.00 MMP2 (0.57) MMP2MMP9PLAUHPNITGB3
Hydrochloric Acid SCHEMBL920895 0.99 MMP2 (0.56) MMP2MMP9PLAUHPNITGB3
Hydrochloric Acid SCHEMBL11406948 0.99 MMP2 (0.56) MMP2MMP9PLAUHPNITGB3
Hydrochloric Acid SCHEMBL15537019 0.98 MMP2 (0.55) MMP2MMP9PLAUHPNITGB3
SCHEMBL1305743 0.89 MMP2 (0.56) MMP2MMP9PLAUHPNITGB3
SCHEMBL1305745 0.89 MMP2 (0.56) MMP2MMP9PLAUHPNITGB3
SCHEMBL5490595 0.88 PLAU (0.45) MMP2MMP9PLAUHPNITGB3
SCHEMBL28509074 0.87 MMP2 (0.60) MMP2MMP9PLAUHPNITGB3
SCHEMBL20008635 0.87 MMP9 (0.67) MMP2MMP9ITGB3ITGA2BSLC1A3
SCHEMBL28212986 0.87 MMP9 (0.67) MMP2MMP9ITGB3ITGA2BSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 785 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680762-A1 OSTOMY OUTPUT INDICATOR HOLLISTER INCORPORATED (US) 2026-01-21 EP claimed
EP-3557816-B1 SELF-DIAGNOSIS METHOD FOR COMMUNICATION PROTOCOL OF SECURITY-LEVEL INSTRUMENTATION AND CONTROL SYSTEM OF NUCLEAR POWER PLANT CHINA TECHENERGY CO LTD (CN) 2026-01-14 EP claimed
US-12458582-B2 Stabilized hyaluronic acid CROMA-PHARMA GMBH (AT) 2025-11-04 US claimed
US-20250281579-A1 Methods and Compositions for Oral Administration of Proteins ORAMED PHARMACEUTICALS INC (IL) 2025-09-11 US claimed
US-20250145945-A1 CULTURE MEDIA FOR CULTURING PLURIPOTENT STEM CELLS IN SUSPENSION ACCELLTA LTD. (IL) 2025-05-08 US claimed
CN-119313997-A Safety monitoring method for production process of fused magnesia based on supervision matrix regression 东北大学 2025-01-14 CN claimed
WO-2024192383-A1 OSTOMY OUTPUT INDICATOR HOLLISTER INCORPORATED (US) 2024-09-19 WO claimed
EP-4427588-A2 COMPOSITIONS FOR HEMOLYSIS AND COAGULATION REGULATION AND STABILIZATION OF EXTRACELLULAR VESICLES Streck LLC (US) 2024-09-11 EP claimed
CN-115119829-B Compositions for the modulation of haemolysis and coagulation of extracellular vesicles and stabilization 斯特雷克股份有限公司 2024-07-12 CN claimed
US-20240216325-A1 NUCLEAR FACTOR KAPPA B PATHWAY INHIBITION TO ARREST CALCIFIC AORTIC STENOSIS CORNELL UNIVERSITY 2024-07-04 US claimed
WO-2022072504-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES HEALION BIO, INC. (US) 2022-04-07 WO claimed
CN-114206214-A Compositions, methods and systems for protein corona analysis of biological fluids and uses thereof 禧尔公司 2022-03-18 CN claimed
EP-3946054-A1 COMPOSITIONS, METHODS AND SYSTEMS FOR PROTEIN CORONA ANALYSIS FROM BIOFLUIDS AND USES THEREOF Seer, Inc. (US) 2022-02-09 EP claimed
US-7914542-B2 Devices, systems and methods for treating benign prostatic hyperplasia and other conditions NEOTRACT, INC. (US) 2011-03-29 US claimed
US-20090192439-A1 DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER CONDITIONS NEOTRACT, INC. (US) 2009-07-30 US claimed
US-20090060977-A1 DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER CONDITIONS NEOTRACT, INC. (US) 2009-03-05 US claimed
US-20090018523-A1 DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER CONDITIONS NEOTRACT, INC. (US) 2009-01-15 US claimed
EP-1887976-A2 DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER CONDITIONS Neotract, Inc. (US) 2008-02-20 EP claimed
US-20060276871-A1 Devices, systems and methods for treating benign prostatic hyperplasia and other conditions EXPLORAMED NC2, INC. (US) 2006-12-07 US claimed
WO-2006127431-A2 DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER CONDITIONS NEOTRACT, INC. (US) 2006-11-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458582-B2 Stabilized hyaluronic acid CD44, HSPH1, ACR MMP2 106/4885MMP9 133/4885PLAU 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.